이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PharmaEngine 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hong-Ren Wang

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3.7yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Mar 30

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 18

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

Jan 14

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

Dec 10

CEO

Hong-Ren Wang

3.7yrs

테뉴어

Mr. Hong-Ren Wang, Ph D., is President of PharmaEngine, Inc. since January 20, 2021 and serves as Chief Executive Officer. Mr. Wang holds Ph.D. degree in Materials Science and Engineering from Massachusett...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Wen-Hung Hsu	Representative Director	no data	데이터 없음	데이터 없음
Rui-Wen Wu	Representative Director	6.7yrs	NT$2.33m	데이터 없음
Yi-Hui Lin	Representative Director	6.3yrs	NT$2.33m	데이터 없음
Chih-Li Wang	Independent Director	5.3yrs	NT$1.73m	0.0021% NT$ 264.9k
Ming-Feng Hou	Director	3.1yrs	NT$816.00k	데이터 없음
Chien-Huang Lin	Independent Director	3.1yrs	NT$596.00k	데이터 없음
Ming-Daw Chang	Independent Director	no data	데이터 없음	데이터 없음
Ming-Shiang Wu	Representative Director	no data	데이터 없음	데이터 없음
Zhangyao Xu	Chairman	no data	데이터 없음	데이터 없음

5.3yrs

평균 재임 기간

경험이 풍부한 이사회: 4162 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

PharmaEngine 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

PharmaEngine, Inc., Annual General Meeting, May 24, 2024

Less than half of directors are independent

PharmaEngine, Inc. Announces Change of Board of Directors Chairperson

PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022

Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee

Less than half of directors are independent

Recent updates

Now 21% overvalued

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Dividend sustainability

Dividend reduced to NT$1.50

PharmaEngine, Inc. to Report Q2, 2024 Results on Jul 25, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors

PharmaEngine, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: NT$1.91 (vs NT$2.22 in FY 2022)

New major risk - Revenue and earnings growth

PharmaEngine, Inc., Annual General Meeting, May 24, 2024

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers

Upcoming dividend of NT$2.00 per share at 2.4% yield

Second quarter 2023 earnings released: EPS: NT$0.52 (vs NT$0.56 in 2Q 2022)

New major risk - Revenue and earnings growth

PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application

New major risk - Dividend sustainability

PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to NT$107

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Now 20% undervalued

PharmaEngine, Inc. Announces Change of Board of Directors Chairperson

PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022

Investor sentiment improved over the past week

Upcoming dividend of NT$2.70 per share

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Pharmaengine, Inc. Announces Dividend for 2021,Payment Date of Cash Dividend Distribution Is September 2, 2022

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee

Now 25% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target decreased to NT$73.50

Less than half of directors are independent

Investor sentiment improved over the past week

PharmaEngine, Inc., Annual General Meeting, May 27, 2022

Now 21% undervalued

Third quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$1.14 (vs NT$0.099 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.52 (vs NT$0.34 in 1Q 2020)

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Full year 2020 earnings released: EPS NT$4.15 (vs NT$0.29 in FY 2019)

PharmaEngine, Inc., Annual General Meeting, May 31, 2021

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

New 90-day high: NT$66.90

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day low: NT$48.60

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

New 90-day low: NT$53.70

Analysts lower revenue estimates to NT$384.0m

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

New 90-day low: NT$53.90

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.13

New 90-day low: NT$56.70

New 90-day low: NT$59.10

New 90-day low: NT$64.70

First half earnings released

First half earnings released

Upcoming Dividend of NT$0.50 Per Share

CEO

테뉴어